In this view, therapeutics that directly target IL-31 in CTCL could prove useful beyond the management of pruritus and help overcome disease-related immunosuppression to fire up anti-lymphoma cell-mediated responses. The gene discussed is IL31; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.